EDINBURGH, Scotland--(BUSINESS WIRE)--Synpromics is pleased to announce positive data presented today by a key partner, uniQure (NASDAQ:QURE), at the European Society of Gene and Cell Therapy conference in Lausanne, Switzerland. The study used uniQure’s next-generation liver-directed gene therapy system that incorporates a short, highly-selective and powerful liver promoter that was developed by Synpromics.
The study, the first conducted in an advanced pre-clinical model using technology developed by Edinburgh-based Synpromics, demonstrates that the promoter is at least eight-times more potent than the current industry standard, providing uniQure with a powerful tool from which to drive the development of a variety of liver-directed gene therapies.
Commenting on the results, Dr Michael L Roberts, Founder & CSO of Synpromics, said: “This is fantastic data and shows the translatability of our company’s technology to advanced disease relevant models. This is the culmination of a productive partnership with uniQure in which we have worked closely to deliver a highly selective promoter, whose performance has exceeded initial expectations. This promoter enables uniQure to develop safer, targeted gene therapies for liver disease.”
This positive data supports the application of Synpromics’ technology in cell and gene therapies and further cements the company’s position as the leader in gene control.
ENDS
Notes to Editors
About Synpromics
Synpromics is the leader in gene control,
improving human health by enabling safer, more effective cell and gene
medicines through proprietary genomics, bioinformatics and intelligent
data-driven design. The Company has developed PromPT®, its
multi-dimensional bioinformatics database, that enables product-specific
promoter design and selection empowering the next generation of cell and
gene based medicines and bioprocessing applications. The company
operates in a diverse range of fields, including broad applications in
cell and gene based medicine, biologics manufacturing and viral vector
bioprocessing. Current partners include Audentes, Biomarin, uniQure,
AGTC, Solid Biosciences, Homology Medicines Inc, Adverum
Biotechnologies, GE Healthcare and Sartorius-Stedim Cellca, as well as
numerous undisclosed partners in the pharmaceutical sector.
About synthetic promoters
Naturally occurring promoters
have evolved for biological functions but have limitations when utilised
in industrial or therapeutic applications. Synthetic promoters with DNA
sequences not found in nature are designed to better regulate gene
activity and precisely control protein production. Synpromics creates
highly specific promoters designed to drive gene expression at the
desired level and specificity in any cell type, tissue or environmental
condition. Each synthetic promoter represents a novel invention and thus
can be patented.
For more information visit www.synpromics.com
